Inspire Medical Systems (INSP) shares have seen some movement recently. This gives investors a chance to take a closer look at the company’s fundamentals and performance compared to previous months. There could be opportunities for those tracking valuation trends.

After a volatile stretch in recent months, Inspire Medical Systems’ 1-year total shareholder return stands at -52.53% and its year-to-date share price return is down 55.83%. While long-term performance has been challenging, investors may be noticing hints of momentum returning, given the recent 1-month share price gain of 7.13%.

If you’re watching how trends evolve across healthcare, consider what you might discover with our curated See the full list for free.

With shares trading well below recent analyst targets but showing signs of short-term strength, the key question is whether Inspire Medical Systems presents clear value for investors right now, or if the current price already reflects all future growth potential.

Most Popular Narrative: 21.7% Undervalued

With the narrative’s fair value calculation at $106.79, Inspire Medical Systems' last close of $83.57 sets up a debate on whether the market is missing out or seeing real risks. The stage is set for a closer look at the main catalysts behind this sizable gap.

Expanded coverage and proposed reimbursement increases for Inspire's procedures (notably the expected 2026 Medicare OPPS rule enhancements and near-complete payer coverage of the new CPT code) will reduce patient out-of-pocket costs and incentivize additional adoption. This supports both revenue growth and longer-term earnings visibility.

Curious how reimbursement shifts and expanding coverage could reshape future profits and fuel that narrative’s upside? The real story includes some bold growth assumptions behind both revenue and margin projections. Discover which aggressive financial moves got factored into this price target. Read the full analysis to find out what makes this valuation tick.

Result: Fair Value of $106.79 (UNDERVALUED)

However, ongoing operational delays and the heavy reliance on Inspire V’s rollout could present challenges to revenue growth and test the strength of future earnings recovery.

Another View: What Do Market Multiples Suggest?

Taking a look at how the company is valued compared to the market, Inspire Medical Systems trades at a price-to-earnings ratio of 55.3x. That is much higher than the peer average of 31.6x, the industry’s 27.9x, and even further above the 29.2x fair ratio the market could move toward. This sizable gap signals that investors are pricing in a brighter future, but it also raises the question: is too much good news already factored in?

Build Your Own Inspire Medical Systems Narrative

If you have a different perspective or want to dive deeper into the numbers yourself, you can put together your own view on Inspire Medical Systems in just a few minutes. Do it your way

A great starting point for your Inspire Medical Systems research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Smart investors seize fresh opportunities while others watch from the sidelines. Why limit yourself when standout stocks are just a click away on Simply Wall Street?

• Tap into innovation by checking out these 27 AI penny stocks that are using artificial intelligence to unlock new profit frontiers across industries.
• Energize your portfolio with the steady returns from these 18 dividend stocks with yields > 3%, which consistently deliver yields above 3% and prioritize shareholder value.
• Get ahead of market trends and spot hidden bargains by scanning these 894 undervalued stocks based on cash flows before others realize their true potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.